Table 2.
Incidence of comorbidities on MTX monotherapy in the three registers
| UK JIA Biologics Registers | BiKeR | JuMBO | Pharmachild | |||||
|---|---|---|---|---|---|---|---|---|
| Total number of patients | 1065 | 544 | 2462a | |||||
| ILAR | ||||||||
| Oligoarthritis | 372 (35%) | 179 (33%) | 988 (40%) | |||||
| (Persistent) | 194 (18%) | 100 (18%) | 623 (25%) | |||||
| (Extended) | 178 (17%) | 79 (15%) | 365 (15%) | |||||
| Polyarticular RF− | 341 (32%) | 140 (26%) | 692 (28%) | |||||
| Polyarticular RF+ | 84 (8%) | 30 (6%) | 116 (5%) | |||||
| Systemic | 46 (4%) | 15 (3%) | 202 (8%) | |||||
| Psoriatic | 83 (8%) | 57 (10%) | 84 (3%) | |||||
| Esthesitis | 71 (7%) | 104 (19%) | 218 (9%) | |||||
| Undiff. | 35 (3%) | 19 (3%) | 162 (7%) | |||||
| Unknown | 33 (3%) | 0 (0%) | 0 (0%) | |||||
| Total exposure, years | 2499 | 2226 | 642 | 1659 | ||||
| Frequency, N | Rate per 100 person years (95% CI) | Frequency, N | Rate per 100 person years (95% CI) | Frequency, N | Rate per 100 person years (95% CI) | Frequency, N | Rate per 100 person years (95% CI) | |
| Uveitis | 41 patients, N = 952 | 2.2 (1.6, 3.0) | No patients, N = 544 | – | No patients, N = 544 | – | 3 patients, N = 1967 | 0.22 (0.05, 0.64) |
| MAS (systemic JIA only) | 1 patient, N = 42 | 1.2 (0.2, 8.3) | No patients, N = 82 | – | No patients, N = 82 | – | 1 patient, N = 177 | 1.57 (0.04, 8.74) |
| Varicella | 50 patients, N = 1065 | 2.4 (1.8, 3.1) | No patients, N = 544 | – | No patients, N = 544 | – | 9 patients, N = 2462 | 0.55 (0.25, 1.04) |
| Herpes zoster | 12 patients, N = 1065 | 0.5 (0.3, 1.0) | 1 patient, N = 544 | 0.04 (0.001, 0.24) | 2 patients, N = 544 | 0.3 (0.03, 1.1) | 2 patients, N = 2462 | 0.12 (0.01, 0.44) |
| Varicella + herpes zoster | 61 patients, 25 (41%) hospitalized, N = 1065 | 2.9 (2.3, 3.8) | 1 patient, 0 (0%) hospitalized, N = 544 | 0.04 (0.001, 0.24) | 2 patients, 0 (0%) hospitalized N = 544 | 0.3 (0.03, 1.1) | 11 patients, 1 (9%) hospitalized, N = 2462 | 0.67 (0.33, 1.20) |
| TB | No patients, N = 1062 | – | No patients, N = 544 | – | 1 patient, N = 544 | 0.15 (0.02, 1.11) | 3 patients, N = 2430 | 0.18 (0.04, 0.53) |
a
Number of Pharmachild patients ever treated with MTX monotherapy is greater than the number reported on MTX monotherapy at registration (Table 1).